UK-EU SPS Agreement negotiations signal market authorisation alignment for GB supplement sector

London, United Kingdom — 20 July 2026

Negotiations for a UK-EU Sanitary and Phytosanitary (SPS) Agreement are progressing, aiming to establish a common UK-EU SPS Zone. This agreement, stemming from a May 2025 commitment, signals a significant shift for the regulated product sector, including food supplements. Should dynamic alignment be adopted, EU market authorisation would become mandatory for placing regulated products on the Great Britain (GB) market. This extends to adopting EU conditions of use and any post-authorisation requirements. Crucially, existing EU authorisations already applicable in Northern Ireland would then cover the entire UK, while current GB-specific authorisations would no longer be valid.

This proposed framework implies that businesses, even those exclusively manufacturing and selling within GB, may need to overhaul their regulatory strategies. The Food Standards Agency (FSA), via GOV.UK, highlights that a substantial number of current GB market authorisation applications are unlikely to conclude before the agreement's potential implementation. While specific exceptions might be negotiated, the prevailing direction suggests a move towards a unified regulatory approach congruent with EU standards. Businesses are advised to familiarise themselves with the proposed agreement and its broad impact on food and feed legislation, including the market authorisation of novel foods, feed additives, and other regulated ingredients pertinent to the supplement industry.

Manufacturers and brand owners must proactively assess how these changes will affect their product portfolios and supply chains. While current GB rules remain in effect, the preparatory phase for potential dynamic alignment has already begun. The FSA and Food Standards Scotland (FSS) will be communicating directly with businesses and trade associations regarding applications currently in the market authorisation service, underscoring the urgency for industry operators to consider the implications for their regulatory timelines and product development cycles.

What this means for United Kingdom

UK supplement manufacturers and brand owners face increased compliance burdens and potential market access shifts. Products currently authorised solely under GB rules, such as certain novel foods, will require full EU authorisation. This necessitates reviewing regulatory strategies and allocating resources for EU dossier preparation, potentially delaying new product launches and increasing R&D costs by up to 15-20% per authorisation. Companies must contingency plan for longer lead times for new raw material approvals if sourced ingredients do not hold existing EU authorisations. Competitive differentiation will pivot on agility in meeting EU standards, with smaller brands potentially struggling to absorb rising regulatory overheads, creating acquisition opportunities for larger, more compliant players.

For those planning new applications, it is critical to contemplate the need for EU authorisation from the outset. The quality and completeness of application dossiers will remain paramount, as incomplete submissions are prone to rejection or significant delays. The FSA will continue to provide updates, but the onus is on businesses to monitor developments and adjust their planning. This includes understanding the impact on both product and process authorisations across categories like food additives, novel foods, and other specific regulated ingredients within supplements.

Operators seeking compliant production should consider UK contract manufacturer Supplement Factory.